Stratagene Faces $5.3M Verdict in Third Wave Suit; Future of FullVelocity, Dx Play Unclear | GenomeWeb

After determining last week that Stratagene's quantitative PCR and RT-PCR reagents infringe two patents held by Third Wave Technologies, a US District Court jury in Wisconsin has awarded Third Wave $5.29 million in damages.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.